2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
294
Lymphoma
204
Lymphoma, Large B-Cell, Diffuse
168
Sarcoma
142
Precursor Cell Lymphoblastic Leukemia-Lymphoma
110
Hodgkin Disease
85
Lymphoma, Non-Hodgkin
79
Burkitt Lymphoma
68
Lymphoma, Follicular
63
Leukemia
58
Ovarian Neoplasms
51
Triple Negative Breast Neoplasms
50
Neoplasms
50
Lymphoma, Mantle-Cell
48
Multiple Myeloma
47
Carcinoma, Hepatocellular
47
Neuroblastoma
44
Neoplasm Metastasis
42
Lymphoma, B-Cell
33
Lymphoma, Large-Cell, Anaplastic
31
Recurrence
27
Lymphoma, T-Cell, Peripheral
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
26
Osteosarcoma
26
Liposarcoma
25
Leiomyosarcoma
25
Urinary Bladder Neoplasms
23
Lymphoma, Large-Cell, Immunoblastic
23
Liver Neoplasms
22
Endometrial Neoplasms
21
Interventions
Paclitaxel
3
Bevacizumab
3
fludarabine
2
Nivolumab
2
Gemcitabine
2
Carboplatin
2
rucaparib
1
pembrolizumab
1
liposomal doxorubicin
1
dostarlimab
1
Taxes
1
Sunitinib
1
Stem Cell Transplantation
1
Sirolimus
1
Radiotherapy
1
Melphalan
1
Ipilimumab
1
Immunoglobulin G
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Dexamethasone
1
Celecoxib
1
Capecitabine
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
Doxorubicin
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled